Skip Content
You are currently on the new version of our website. Access the old version .

10 Results Found

  • Review
  • Open Access
18 Citations
14,564 Views
34 Pages

Inhibitors of NAD+ Production in Cancer Treatment: State of the Art and Perspectives

  • Moustafa S. Ghanem,
  • Irene Caffa,
  • Fiammetta Monacelli and
  • Alessio Nencioni

8 February 2024

The addiction of tumors to elevated nicotinamide adenine dinucleotide (NAD+) levels is a hallmark of cancer metabolism. Obstructing NAD+ biosynthesis in tumors is a new and promising antineoplastic strategy. Inhibitors developed against nicotinamide...

  • Article
  • Open Access
13 Citations
4,106 Views
15 Pages

Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors

  • Jorge Franco,
  • Francesco Piacente,
  • Melanie Walter,
  • Simone Fratta,
  • Moustafa Ghanem,
  • Andrea Benzi,
  • Irene Caffa,
  • Alexander V. Kurkin,
  • Andrea Altieri and
  • Alberto Del Rio
  • + 5 authors

NAPRT, the rate-limiting enzyme of the Preiss–Handler NAD biosynthetic pathway, has emerged as a key biomarker for the clinical success of NAMPT inhibitors in cancer treatment. Previous studies found that high protein levels of NAPRT conferred...

  • Article
  • Open Access
3 Citations
2,699 Views
12 Pages

Metabolic Alterations in NADSYN1-Deficient Cells

  • Nils W. F. Meijer,
  • Johan Gerrits,
  • Susan Zwakenberg,
  • Fried J. T. Zwartkruis,
  • Nanda M. Verhoeven-Duif and
  • Judith J. M. Jans

12 December 2023

NAD synthetase 1 (encoded by the gene NADSYN1) is a cytosolic enzyme that catalyzes the final step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+) from tryptophan and nicotinic acid. NADSYN1 deficiency has recently been added to the s...

  • Review
  • Open Access
55 Citations
15,530 Views
35 Pages

Advances in NAD-Lowering Agents for Cancer Treatment

  • Moustafa S. Ghanem,
  • Fiammetta Monacelli and
  • Alessio Nencioni

14 May 2021

Nicotinamide adenine dinucleotide (NAD) is an essential redox cofactor, but it also acts as a substrate for NAD-consuming enzymes, regulating cellular events such as DNA repair and gene expression. Since such processes are fundamental to support canc...

  • Review
  • Open Access
20 Citations
7,582 Views
21 Pages

9 November 2021

Neurodegenerative diseases result in the progressive deterioration of the nervous system, with motor and cognitive impairments being the two most observable problems. Motor dysfunction could be caused by motor neuron diseases (MNDs) characterized by...

  • Article
  • Open Access
6 Citations
2,713 Views
11 Pages

Targeting of Glucose Transport and the NAD Pathway in Neuroendocrine Tumor (NET) Cells Reveals New Treatment Options

  • Jochen Winter,
  • Rudolf Kunze,
  • Nadine Veit,
  • Stefan Kuerpig,
  • Michael Meisenheimer,
  • Dominik Kraus,
  • Alexander Glassmann and
  • Rainer Probstmeier

23 February 2023

(1) Background: the potency of drugs that interfere with glucose metabolism, i.e., glucose transporters (GLUT) and nicotinamide phosphoribosyltransferase (NAMPT) was analyzed in neuroendocrine tumor (NET, BON-1, and QPG-1 cells) and small cell lung c...

  • Article
  • Open Access
5 Citations
3,667 Views
14 Pages

Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia

  • Saki Matsumoto,
  • Paulina Biniecka,
  • Axel Bellotti,
  • Michel A. Duchosal and
  • Aimable Nahimana

27 January 2023

Targeting NAD depletion in cancer cells has emerged as an attractive therapeutic strategy for cancer treatment, based on the higher reliance of malignant vs. healthy cells on NAD to sustain their aberrant proliferation and altered metabolism. NAD dep...

  • Article
  • Open Access
20 Citations
5,101 Views
18 Pages

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery

  • Moustafa S. Ghanem,
  • Irene Caffa,
  • Alberto Del Rio,
  • Jorge Franco,
  • Marco Daniele Parenti,
  • Fiammetta Monacelli,
  • Michele Cea,
  • Amr Khalifa,
  • Aimable Nahimana and
  • Francesco Piacente
  • + 5 authors

Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransfe...

  • Review
  • Open Access
4 Citations
9,775 Views
26 Pages

5 September 2024

Nicotinamide adenine dinucleotide (NAD+) is an important cofactor for both metabolic and signaling pathways, with the dysregulation of NAD+ levels acting as a driver for diseases such as neurodegeneration, cancers, and metabolic diseases. NAD+ plays...

  • Article
  • Open Access
2,352 Views
20 Pages

Structure-Function Insights into the Dual Role in Nucleobase and Nicotinamide Metabolism and a Possible Use in Cancer Gene Therapy of the URH1p Riboside Hydrolase

  • Alejandra Angela Carriles,
  • Laura Muzzolini,
  • Claudia Minici,
  • Paola Tornaghi,
  • Marco Patrone and
  • Massimo Degano

The URH1p enzyme from the yeast Saccharomyces cerevisiae has gained significant interest due to its role in nitrogenous base metabolism, particularly involving uracil and nicotinamide salvage. Indeed, URH1p was initially classified as a nucleoside hy...